New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis [Corrigendum]

Abstract

Frati F, Cecchi L, Scala E, Ridolo E, Dell’Albani I, Makrì E, Pajno GB, Incorvaia C. Biologics: Targets and Therapy. 2014;8:221–226.On page 223, Figure 1 should be replaced with the revised version as shown below:On page 224, line 4 in the left column, "many" should be replaced with "all".On page 224, line 7 in the left column, "but only the major allergen Phl p 5 is measured in μg" should be replaced with "such as group 1 and group 5 allergens (Figure1, Table 2)".On page 224, line 9 in the left column, the reference to "(Figure 1)" should be removed.Read the original article